By 2025, the global burden of obesity and metabolic diseases continues to escalate, with the U.S. obesity rate climbing to 42.4%. Traditional therapies face limitations due to restricted efficacy and significant side effects. Against this backdrop, an individual U.S. seller client ordered one box of Retatrutide 60mg (specification: 60mg/vial × 10 vials/box) through the Bloom Tech platform for personal obesity treatment and subsequent market validation.
|
|
|
|
|
|
|
|
Application
Retatrutide is an investigational triple hormone receptor agonist currently being developed primarily for the treatment of obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASLD). Details are as follows:
Obesity
Mechanism of Action: Retatrutide synergistically regulates metabolism and appetite by simultaneously activating GLP-1, GIP, and glucagon receptors. GLP-1 and GIP lower blood glucose and reduce food intake by stimulating insulin secretion and suppressing appetite; glucagon promotes weight loss by increasing energy expenditure and lipolysis while reducing hepatic fat accumulation.
Clinical Efficacy: Clinical trials demonstrate significant therapeutic effects of Retatrutide in obese patients. For example, after 48 weeks of treatment at the highest dose (12 mg), average weight loss reached 24.2% (approximately 58 lbs/26.2 kg), significantly outperforming the placebo group (2.1%). In another trial, waist circumference changes ranged from -2.1 cm to -10.2 cm among individuals treated for 26 weeks.
Type 2 Diabetes
Mechanism of Action: Retatrutide lowers blood glucose levels by activating GLP-1 and GIP receptors, thereby promoting insulin secretion and inhibiting glucagon secretion.
Clinical Effects: In type 2 diabetes patients, Retatrutide significantly reduced HbA1c levels, with some patients approaching normal glucose ranges. For example, after 6 months of Retatrutide treatment at various doses, HbA1c decreased by 1.3% to 2.0% in type 2 diabetes patients. Additionally, patients receiving 12 mg of Retatrutide achieved an average weight reduction of 16.9% over 8 months, equivalent to an absolute weight loss of 34.4 jin (approximately 17.2 kg), exceeding the placebo group by 6.6 jin (approximately 3.0 kg).
Metabolic dysfunction-associated steatohepatitis (MASLD)
Mechanism of action: Retatrutide improves liver function by reducing hepatic fat accumulation.
Clinical efficacy: In MASLD patients, Retatrutide demonstrated potential to reduce hepatic fat content. For instance, in MASLD patients, the 8 mg and 12 mg dose groups showed reductions in hepatic fat content of 81.4% and 82.4%, respectively, over 24 weeks. After 48 weeks of treatment with the two highest doses of Retatrutide in patients with non-alcoholic steatohepatitis (NASH), 9 out of 10 patients achieved normalization of hepatic fat content.
side effects
The side effects of Retatrutide primarily include gastrointestinal symptoms, increased heart rate, sensory disturbances, and skin sensitivity, as detailed below:
Gastrointestinal symptoms
These represent the most common side effects of Retatrutide, including nausea, vomiting, diarrhea, and constipation. These symptoms are typically dose-related, and initiating treatment with a lower starting dose (e.g., 2mg) can partially alleviate these adverse events. In clinical trials, nausea, vomiting, and diarrhea occurred at relatively high rates, but most symptoms were mild to moderate and gradually diminished or resolved with prolonged treatment.
Increased Heart Rate
Some patients may experience elevated heart rate after using Retatrutide. This side effect typically resolves within 24 weeks, but patients should remain vigilant about heart rate changes and seek prompt medical attention if abnormalities occur.
Sensory Disturbances
In Phase III clinical trials, some patients experienced dysesthesia-an unpleasant or abnormal sensory perception. This side effect was more common in the highest dose group (12 mg), occurring in approximately 20.9% of cases. Most instances were mild and rarely led to treatment discontinuation.
Skin Sensitivity
Skin Sensitivity: Some patients may experience increased skin sensitivity to touch, pain, pressure, or heat after using Retatrutide. While the incidence of these symptoms was relatively low in clinical trials, they warrant attention.
Does retatrutide cause muscle atrophy
Retatrutide typically does not directly cause muscle atrophy, but minimal muscle loss may occur during weight loss, necessitating strategic optimization of body composition. The following provides a detailed analysis:
As a GLP-1 receptor agonist, liraglutide primarily achieves weight loss by suppressing appetite, delaying gastric emptying, and regulating metabolism. Multiple studies indicate its weight loss effects primarily stem from reduced adipose tissue, particularly visceral fat. For instance, the LEAD studies showed that after 12 weeks of liraglutide treatment, patients experienced an average reduction of 3.8 kg in total fat mass and 1.5 kg in total muscle mass, with fat loss significantly exceeding muscle loss. Another study indicated that approximately 63% of obese or overweight patients achieved at least a 5% weight reduction after one year of liraglutide use, with muscle loss accounting for a relatively small proportion.
Although muscle loss is relatively low, muscle mass still requires attention during long-term weight loss. Muscle wasting is typically associated with increased protein breakdown, metabolic disorders, or malnutrition, and liraglutide itself does not directly cause these mechanisms. However, failing to implement muscle-protective measures during weight loss (such as a high-protein diet or resistance training) may heighten the risk of muscle loss. For instance, when obese patients experience weight regain, the increased body fat is often greater than muscle mass, making further optimization of body composition crucial.
To minimize muscle loss, the following strategies are recommended during liraglutide use:
High-protein diet: Increasing protein intake stimulates protein synthesis, counteracting the effects of increased breakdown.
Resistance training: Regular strength training helps maintain muscle mass and improves metabolic health.
Body composition monitoring: Periodically assess fat-to-muscle ratios using body fat scales or medical imaging (e.g., CT scans) to adjust treatment plans promptly.
Additionally, liraglutide's side effects (e.g., gastrointestinal reactions, hypoglycemia risk) may indirectly impact muscle health. For instance, nausea or vomiting can lead to inadequate nutrient intake, thereby affecting muscle synthesis. Therefore, closely monitor bodily responses during treatment and consult healthcare professionals to adjust dosages or explore combination therapy options.
How much protein should be consumed while taking Retatrutide
When taking Retatrutide, the recommended daily protein intake is calculated based on target body weight: approximately 1 gram of protein per pound (about 0.45 kg) of target body weight. For example, if your current weight is 200 pounds but your target healthy weight is 140 pounds, your daily protein goal would be 140 grams.
Target Weight Calculation Principle
When using Retatrutide for weight loss, protein intake should be based on the target weight, not the current weight. This approach prevents insufficient protein intake due to weight loss, thereby maintaining muscle mass and supporting organ function.
Adjustments for Renal Impairment
Individuals with renal impairment should consult a nephrologist or primary care physician to adjust daily protein intake based on kidney function. For example, chronic kidney disease patients may need to limit protein to 0.5-0.7 grams per kilogram of body weight per day, prioritizing high-quality animal proteins (e.g., egg whites, milk, fish, lean meats).
Key Considerations for Protein Intake
Prioritize high-quality protein: Ensure 50%-70% of protein comes from animal sources (e.g., egg whites, milk, fish, lean meat), which are rich in essential amino acids and offer superior absorption and utilization.
Avoid overestimating intake: Most people tend to overestimate protein consumption; use food logs or nutrition tracking tools for accurate calculation.
Lifestyle adjustments: While taking Retatrutide, simultaneously control calorie intake, maintain physical activity, and ensure adequate sleep to optimize weight loss outcomes.
Necessity of Long-Term Use
Retatrutide requires at least 6 months of continuous use to lower the body's weight "set point." Long-term use facilitates sustained weight management. During this period, ongoing monitoring of protein intake and dietary plan adjustments are critical.